AEON Biopharma, Inc.
AEON
$0.40
-$0.0093-2.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -31.06% | -23.84% | 13.43% | 37.60% | 41.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.34% | -40.18% | -15.40% | 0.05% | 8.18% |
| Operating Income | 47.34% | 40.18% | 15.40% | -0.05% | -8.18% |
| Income Before Tax | 110.92% | 103.48% | -291.60% | -644.60% | -650.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 110.92% | 103.48% | -291.60% | -644.60% | -650.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 110.92% | 103.48% | -291.60% | -644.60% | -650.14% |
| EBIT | 47.34% | 40.18% | 15.40% | -0.05% | -8.18% |
| EBITDA | 47.43% | 40.24% | 15.44% | -0.02% | -8.13% |
| EPS Basic | 115.07% | 103.33% | -796.46% | -1,897.94% | -1,615.07% |
| Normalized Basic EPS | -75.92% | -67.55% | -484.57% | -541.12% | -168.68% |
| EPS Diluted | 114.94% | 103.27% | -796.46% | -1,889.40% | -1,605.77% |
| Normalized Diluted EPS | -75.89% | -67.55% | -484.57% | -541.12% | -168.68% |
| Average Basic Shares Outstanding | -58.54% | -67.96% | -68.73% | -50.73% | -32.44% |
| Average Diluted Shares Outstanding | -58.52% | -67.96% | -68.73% | -50.73% | -32.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
